CPD identified that BC patients are most prominently distinguished by their reduced IL-10 response across many cell populations, particularly in B and CD8+ cells, (component 6) (Fig. 2i) and basal pSmad2/3 and pSTAT4 across many populations (component 10) (Fig. 2k). The gene discussed is CD8A; the disease is breast cancer.